London
· Delayed Price · Currency is GBP · Price in GBXOndine Biomedical Company Description
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally.
Its product platform is Photodisinfection, a light-based antimicrobial technology that provides destruction of pathogens without causing antibiotic resistance.
The company’s lead product is Steriwave, a nasal photodisinfection solutions that destroys bacteria, viruses, and fungi colonizing the nose which leads to healthcare-associated infections.
Its product pipeline also includes the development of topical antiviral therapy for the upper respiratory tract to reduce SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds.
The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Carolyn Cross |
Contact Details
Address: 1100 Melville Street Vancouver, British Columbia V6E 4A6 Canada | |
| Phone | 604-669-0555 |
| Website | ondinebio.com |
Stock Details
| Ticker Symbol | OBI |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA68234M2058 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carolyn Cross | Chief Executive Officer |
| Kwong Choo | Chief Financial Officer |
| William Kanz | Chief Operating Officer |